Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients

World Journal of Surgical Oncology

Research

Xinmin Yu¹  Jun Zhao¹  Lei Shi¹  Wei Hong¹  Xun Shi¹  Yan Sun¹ 

[1] Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, 38 Guangji road, 310022, Hangzhou, Zhejiang province, People’s Republic of China;Department of Medical Oncology, Zhejiang Cancer Hospital, 38 Guangji road, Gongshu District, 310022, Hangzhou, People’s Republic of China;

关键词: Lung adenocarcinoma;    IASLC/ATS/ERS classification;    Stage IB;    Prognosis;    EGFR mutation;   

DOI  :  10.1186/1477-7819-12-148

 received in 2013-10-12, accepted in 2014-05-04,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundA new lung adenocarcinoma classification proposed by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) has recently been published. This study aimed to investigate the utility of the new histological classification for identifying the prognostic subtypes of adenocarcinomas in stage IB patients.Correlations between the classification and the presence of epidermal growth factor receptor (EGFR) mutation status was also studied.MethodsOne hundred and thirty-six patients with stage IB lung adenocarcinoma operated on in Zhejiang Cancer Hospital were identified between 2002 and 2011. Patients overall survival and disease-free survival were calculated using Kaplan-Meier and Cox regression analyses. EGFR mutations were detected using the amplification refractory mutation system.ResultsA total of 136 cases were included in current study, of which 38 were papillary predominant, 39 were acinar predominant, 22 were micropapillary predominant, 21 were lepidic predominant subtypes, 14 were solid predominant, and 2 were variants of invasive adenocarcinoma. Patients with micropapillary- and solid-predominant tumors had the lowest five-year disease-free survival (28.4 and 36.7%, respectively). Univariate and multivariate analysis showed that the micropapillary-predominant subtype was an independent predictor of disease-free survival (P = 0.0041 and 0.048, respectively), but not overall survival (P = 0.175 and 0.214, respectively). EGFR mutations were significantly associated with the micropapillary-predominant subtype patients (P = 0.0026). The EGFR mutation frequency is lower in the solid-predominant subtype than other subtypes (P = 0.0508).ConclusionsThe predominant subtype in the primary tumor was associated with prognosis in resected stage IB lung adenocarcinoma. The EGFR mutation frequency of micropapillary-predominant subtype is higher than other subtypes.

【 授权许可】

Unknown   
© Sun et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.